Search
Corneal Abrasions
go.drugbank.com/conditions/DBCOND0039241Drugs: FramycetinSynonyms: CA - Corneal abrasionLevosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMacimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels
Irinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigational[A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer. … [A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma.
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany.
Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16727ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases.
Midecamycin
go.drugbank.com/drugs/DB13456Investigational[A33075] Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.[L2791] … In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.